抗pd -1可增强浸润黑色素瘤的th1样Foxp3+调节性T细胞的共刺激,减轻局部免疫抑制。

IF 10.3 1区 医学 Q1 IMMUNOLOGY Journal for Immunotherapy of Cancer Pub Date : 2025-01-06 DOI:10.1136/jitc-2024-009435
Mikhaël Attias, Fernando Alvarez, Tho-Alfakar Al-Aubodah, Roman Istomine, Paige McCallum, Fan Huang, Abrahim Sleiman, Tamiko Nishimura, Sonia V Del Rincón, Yasser Riazalhosseini, Ciriaco A Piccirillo
{"title":"抗pd -1可增强浸润黑色素瘤的th1样Foxp3+调节性T细胞的共刺激,减轻局部免疫抑制。","authors":"Mikhaël Attias, Fernando Alvarez, Tho-Alfakar Al-Aubodah, Roman Istomine, Paige McCallum, Fan Huang, Abrahim Sleiman, Tamiko Nishimura, Sonia V Del Rincón, Yasser Riazalhosseini, Ciriaco A Piccirillo","doi":"10.1136/jitc-2024-009435","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8<sup>+</sup> T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment. As Foxp3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells play an important role in tumor-induced immunosuppression and express PD-1, we hypothesized that anti-PD-1 also increases the functions of melanoma-infiltrating T<sub>reg</sub> cells, which could be detrimental to treatment efficacy.</p><p><strong>Methods: </strong>The cellular and functional dynamics of T<sub>reg</sub> cells were evaluated in C57Bl/6 Foxp3-reporter mice bearing highly immunogenic and PD-1 blockade-sensitive Yale University Mouse Melanoma Exposed to Radiation 1.7 (YUMMER1.7) tumors. T<sub>reg</sub> cell responses in tumors and lymphoid compartments were examined throughout tumor growth or therapy and were assessed ex vivo by multiparametric flow cytometry analysis, with in vitro suppression assays using tumor-infiltrating lymphocytes isolated by fluorescence-activated cell sorting (FACS) and <i>in situ</i> through spatial proteomic and transcriptomic profiling.</p><p><strong>Results: </strong>In this highly immunogenic melanoma model, anti-PD-1 monotherapy yielded high responders (HRs) and low responders (LRs). We show that the potent CD8<sup>+</sup> T cell responses characteristic of HR tumors paradoxically coincide with the expansion of highly-activated, Helios-expressing T<sub>reg</sub> cells. In both HRs and LRs, T<sub>reg</sub> cells co-localize with CD8<sup>+</sup> T cells in immunogenic regions of the tumor and display potent suppressive capacity in vitro. Further characterization revealed that melanoma-infiltrating T<sub>reg</sub> cells progressively acquire T-bet and interferon gamma expression, exclusively in HRs, and induction of this T helper cell 1 (T<sub>h</sub>1)-like phenotype in vitro led to CD8<sup>+</sup> T cell evasion from T<sub>reg</sub> cell-mediated suppression. Using spatial proteomic and transcriptomic profiling, we demonstrate that T<sub>reg</sub> cells display an increased activity of PI3K/Akt signaling in regions of HR tumors with an elevated CD8:T<sub>reg</sub> cell ratio.</p><p><strong>Conclusions: </strong>PD-1 blockade promotes the expansion of a subset of highly-activated T<sub>reg</sub> cells coexpressing PD-1 and Helios. While these cells are potently suppressive outside tumor environments, costimulatory and inflammatory signals present in the tumor microenvironment lead to their local acquisition of T<sub>h</sub>1-like characteristics and loss of suppression of effector T cells.</p>","PeriodicalId":14820,"journal":{"name":"Journal for Immunotherapy of Cancer","volume":"13 1","pages":""},"PeriodicalIF":10.3000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748786/pdf/","citationCount":"0","resultStr":"{\"title\":\"Anti-PD-1 amplifies costimulation in melanoma-infiltrating T<sub>h</sub>1-like Foxp3<sup>+</sup> regulatory T cells to alleviate local immunosuppression.\",\"authors\":\"Mikhaël Attias, Fernando Alvarez, Tho-Alfakar Al-Aubodah, Roman Istomine, Paige McCallum, Fan Huang, Abrahim Sleiman, Tamiko Nishimura, Sonia V Del Rincón, Yasser Riazalhosseini, Ciriaco A Piccirillo\",\"doi\":\"10.1136/jitc-2024-009435\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8<sup>+</sup> T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment. As Foxp3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells play an important role in tumor-induced immunosuppression and express PD-1, we hypothesized that anti-PD-1 also increases the functions of melanoma-infiltrating T<sub>reg</sub> cells, which could be detrimental to treatment efficacy.</p><p><strong>Methods: </strong>The cellular and functional dynamics of T<sub>reg</sub> cells were evaluated in C57Bl/6 Foxp3-reporter mice bearing highly immunogenic and PD-1 blockade-sensitive Yale University Mouse Melanoma Exposed to Radiation 1.7 (YUMMER1.7) tumors. T<sub>reg</sub> cell responses in tumors and lymphoid compartments were examined throughout tumor growth or therapy and were assessed ex vivo by multiparametric flow cytometry analysis, with in vitro suppression assays using tumor-infiltrating lymphocytes isolated by fluorescence-activated cell sorting (FACS) and <i>in situ</i> through spatial proteomic and transcriptomic profiling.</p><p><strong>Results: </strong>In this highly immunogenic melanoma model, anti-PD-1 monotherapy yielded high responders (HRs) and low responders (LRs). We show that the potent CD8<sup>+</sup> T cell responses characteristic of HR tumors paradoxically coincide with the expansion of highly-activated, Helios-expressing T<sub>reg</sub> cells. In both HRs and LRs, T<sub>reg</sub> cells co-localize with CD8<sup>+</sup> T cells in immunogenic regions of the tumor and display potent suppressive capacity in vitro. Further characterization revealed that melanoma-infiltrating T<sub>reg</sub> cells progressively acquire T-bet and interferon gamma expression, exclusively in HRs, and induction of this T helper cell 1 (T<sub>h</sub>1)-like phenotype in vitro led to CD8<sup>+</sup> T cell evasion from T<sub>reg</sub> cell-mediated suppression. Using spatial proteomic and transcriptomic profiling, we demonstrate that T<sub>reg</sub> cells display an increased activity of PI3K/Akt signaling in regions of HR tumors with an elevated CD8:T<sub>reg</sub> cell ratio.</p><p><strong>Conclusions: </strong>PD-1 blockade promotes the expansion of a subset of highly-activated T<sub>reg</sub> cells coexpressing PD-1 and Helios. While these cells are potently suppressive outside tumor environments, costimulatory and inflammatory signals present in the tumor microenvironment lead to their local acquisition of T<sub>h</sub>1-like characteristics and loss of suppression of effector T cells.</p>\",\"PeriodicalId\":14820,\"journal\":{\"name\":\"Journal for Immunotherapy of Cancer\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":10.3000,\"publicationDate\":\"2025-01-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748786/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal for Immunotherapy of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/jitc-2024-009435\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal for Immunotherapy of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jitc-2024-009435","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:靶向程序性细胞死亡蛋白-1 (PD-1)的免疫检查点抑制剂是包括黑色素瘤在内的许多实体瘤的一线治疗方法。PD-1阻断增强黑色素瘤浸润的CD8+ T细胞的效应功能,导致持久的肿瘤缓解。然而,55%的黑色素瘤患者对治疗没有反应。由于Foxp3+调节性T (Treg)细胞在肿瘤诱导的免疫抑制中发挥重要作用并表达PD-1,我们假设抗PD-1也增加了黑色素瘤浸润Treg细胞的功能,这可能不利于治疗效果。方法:在携带高免疫原性和PD-1阻断敏感的耶鲁大学小鼠黑色素瘤暴露于辐射1.7 (YUMMER1.7)肿瘤的C57Bl/6 foxp3报告小鼠中,评估Treg细胞的细胞和功能动力学。在整个肿瘤生长或治疗过程中,研究人员检测了肿瘤和淋巴细胞室中的Treg细胞反应,并通过多参数流式细胞术分析进行了体外评估,利用荧光活化细胞分选(FACS)分离的肿瘤浸润淋巴细胞进行了体外抑制试验,并通过空间蛋白质组学和转录组学分析进行了原位抑制试验。结果:在高免疫原性黑色素瘤模型中,抗pd -1单药治疗产生高反应(HRs)和低反应(LRs)。我们发现,HR肿瘤的强效CD8+ T细胞反应特征与高度激活的表达helios的Treg细胞的扩增矛盾地一致。在HRs和LRs中,Treg细胞与CD8+ T细胞共定位于肿瘤的免疫原区,并在体外显示出强大的抑制能力。进一步的表征表明,黑色素瘤浸润的Treg细胞逐渐获得T-bet和干扰素γ表达,仅在hr中,体外诱导这种T辅助细胞1 (Th1)样表型导致CD8+ T细胞逃避Treg细胞介导的抑制。利用空间蛋白质组学和转录组学分析,研究人员发现,在CD8:Treg细胞比例升高的HR肿瘤区域,Treg细胞显示PI3K/Akt信号活性增加。结论:PD-1阻断可促进高活性Treg细胞亚群的扩增,这些细胞共表达PD-1和Helios。虽然这些细胞在肿瘤外环境具有强大的抑制作用,但肿瘤微环境中存在的共刺激和炎症信号导致它们局部获得th1样特征,并失去对效应T细胞的抑制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Anti-PD-1 amplifies costimulation in melanoma-infiltrating Th1-like Foxp3+ regulatory T cells to alleviate local immunosuppression.

Background: Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8+ T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment. As Foxp3+ regulatory T (Treg) cells play an important role in tumor-induced immunosuppression and express PD-1, we hypothesized that anti-PD-1 also increases the functions of melanoma-infiltrating Treg cells, which could be detrimental to treatment efficacy.

Methods: The cellular and functional dynamics of Treg cells were evaluated in C57Bl/6 Foxp3-reporter mice bearing highly immunogenic and PD-1 blockade-sensitive Yale University Mouse Melanoma Exposed to Radiation 1.7 (YUMMER1.7) tumors. Treg cell responses in tumors and lymphoid compartments were examined throughout tumor growth or therapy and were assessed ex vivo by multiparametric flow cytometry analysis, with in vitro suppression assays using tumor-infiltrating lymphocytes isolated by fluorescence-activated cell sorting (FACS) and in situ through spatial proteomic and transcriptomic profiling.

Results: In this highly immunogenic melanoma model, anti-PD-1 monotherapy yielded high responders (HRs) and low responders (LRs). We show that the potent CD8+ T cell responses characteristic of HR tumors paradoxically coincide with the expansion of highly-activated, Helios-expressing Treg cells. In both HRs and LRs, Treg cells co-localize with CD8+ T cells in immunogenic regions of the tumor and display potent suppressive capacity in vitro. Further characterization revealed that melanoma-infiltrating Treg cells progressively acquire T-bet and interferon gamma expression, exclusively in HRs, and induction of this T helper cell 1 (Th1)-like phenotype in vitro led to CD8+ T cell evasion from Treg cell-mediated suppression. Using spatial proteomic and transcriptomic profiling, we demonstrate that Treg cells display an increased activity of PI3K/Akt signaling in regions of HR tumors with an elevated CD8:Treg cell ratio.

Conclusions: PD-1 blockade promotes the expansion of a subset of highly-activated Treg cells coexpressing PD-1 and Helios. While these cells are potently suppressive outside tumor environments, costimulatory and inflammatory signals present in the tumor microenvironment lead to their local acquisition of Th1-like characteristics and loss of suppression of effector T cells.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer Biochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
17.70
自引率
4.60%
发文量
522
审稿时长
18 weeks
期刊介绍: The Journal for ImmunoTherapy of Cancer (JITC) is a peer-reviewed publication that promotes scientific exchange and deepens knowledge in the constantly evolving fields of tumor immunology and cancer immunotherapy. With an open access format, JITC encourages widespread access to its findings. The journal covers a wide range of topics, spanning from basic science to translational and clinical research. Key areas of interest include tumor-host interactions, the intricate tumor microenvironment, animal models, the identification of predictive and prognostic immune biomarkers, groundbreaking pharmaceutical and cellular therapies, innovative vaccines, combination immune-based treatments, and the study of immune-related toxicity.
期刊最新文献
Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity. Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient during immunotherapy. Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. Urine proteomics defines an immune checkpoint-associated nephritis signature. Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1